

Q-linea announces determined exercise price for warrants series TO 1 and update regarding subscription intentions

Q-linea AB (publ) ("Q-linea" or the "Company") hereby announces that the exercise price for warrants series TO 1 (the "warrants") has been determined to SEK 0.03. The exercise period for the warrants commences on 5 May 2025 and runs up to and including 19 May 2025. The last day for trading in the warrants is 15 May 2025. In addition to the subscription intentions of the Company's major shareholders announced on 16 April 2025, which comprise approximately 61 percent of the outstanding warrants, Q-linea has also received subscription intentions from all members of the Company's Board of Directors and management who hold warrants, corresponding to their full holdings of warrants, totaling approximately 1 percent of the outstanding warrants. This means that subscription intentions totaling approximately 62 percent of the outstanding warrants, corresponding to approximately SEK 40.5 million, have been received from major shareholders, including Ulf Landegren (Landegren Gene Technology AB), Investment AB Öresund, Transferator AB and Fjärde AP-fonden, and the Company's Board of Directors and management, including the Company's CEO Stuart Gander.

Q-linea carried out a rights issue of units in January 2025 (the "**Rights Issue**"). Each unit issued in the Rights Issue consisted of two (2) shares and one (1) warrant series TO 1. One (1) warrant series TO 1 entitles the holder to subscribe for one (1) new share in the Company. The subscription price for the warrants was set at 70 percent of the volume-weighted average price for the Company's share on Nasdaq Stockholm during the period from and including 14 April 2025 up to and including 29 April 2025, however not lower than the quota value of the share (SEK 0.01 per share). The volume-weighted average price during the pricing period amounted to approximately SEK 0.04 per share, and thus the subscription price, in accordance with Euroclear's limitation on two decimal points, is set at SEK 0.03 per share. If all warrants are exercised, Q-linea will thus receive approximately SEK 65.0 million before issue costs (the "**Warrant Programme**").

Subscription intentions

On 16 April 2025, the Company announced that it had received subscription intentions from major shareholders, including Ulf Landegren (Landegren Gene Technology AB), Investment AB Öresund, Transferator AB, and Fjärde AP-fonden, who hold warrants corresponding to approximately 61 percent of the Warrant Programme, corresponding to approximately SEK 39.9 million. In addition to the above, the Company has now also received subscription intentions from all members of the Company's Board of Directors and management who hold warrants corresponding to their full holdings of warrants, totaling approximately 1 percent of the Warrant Program, corresponding to approximately SEK 0.6 million. This means that subscription intentions totaling approximately [62] percent of the Warrant Program, corresponding to approximately SEK 40.5 million, have been received from major shareholders, including Ulf Landegren (Landegren Gene Technology AB), Investment AB Öresund, Transferator AB and Fjärde AP-fonden, and the Company's board of directors and management, including the Company's CEO Stuart Gander.

Summary of instructions and important dates

Holders of warrants who wish to exercise these to subscribe for shares shall give notice regarding such exercise at the latest on 19 May 2025. Warrants that have not been exercised on or before 19 May 2025 expire without value. Holders who do not wish to exercise their warrants may sell them. Trading with warrants is ongoing up to and including 15 May 2025.

Detailed information and instructions for subscription

Exercise of nominee-registered warrants

Holders of warrants who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before 19 May 2025 as different nominees have different processing times and application deadlines.

Exercise of directly registered warrants

Holders of warrants who have their holdings directly registered (holdings on a VP account) must notify the exercise of warrants by filling in and submitting an application form for the exercise, so that the application form is received by the issuing agent, Vator Securities AB, no later than 19 May 2025.

Application form and information folder will be held available on the Company's and Vator Securities AB's respective websites (www.qlinea.com and www.vatorsecurities.se) in connection with the commencement of the exercise period. Please note that payment for the new shares must be received by Vator Securities no later than 19 May 2025 in accordance with the instructions on the application form.

Trading in TO1

Holders who do not wish to exercise their warrants may sell them on Nasdaq Stockholm. The warrants are traded up to and including 15 May 2025 under the short name QLINEA TO1 and with ISIN code SE0023641121. Warrants that are not sold on 15 May 2025 at the latest or exercised on 19 May 2025 at the latest will expire without value.

Outcome and delivery of new ordinary shares

The outcome of the exercise of warrants will be published via a press release on or around 21 May 2025. Shares that have been subscribed and paid for may be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into shares in Q-linea.

Change in share capital and number of shares

Upon full exercise of all 2,165,560,862 warrants series TO1, the share capital will increase by a maximum of SEK 21,655,608.62 to SEK 66,138,498.58 through the issuance of a maximum of 2,165,560,862 new shares, resulting in that the total number of outstanding shares in the Company will increase from 4,448,288,096 to 6,613,848,958. Upon full exercise of all warrants series TO1, the dilution amounts to approximately 32.7 percent.

Complete terms and conditions for the warrants

Complete terms and conditions for the warrants are available on the Company's website, www.qlinea.com

Advisers

Vator Securities AB is acting as financial advisor and issuing agent in connection with the Rights Issue. Advokatfirman Lindahl is acting as legal advisor to the Company in connection with the Rights Issue.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Q-linea. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Q-linea has only been made through the prospectus published by Q-linea on 10 January 2025. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website, www.qlinea.com.

Since Q-linea conducts essential services according to the Swedish Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar), the exercise of warrants for subscription of shares may require review by the Inspectorate of Strategic Products (ISP). The Company will, no later than in connection with the commencement of the exercise period for the warrants, publish more information about this on the Company's website, www.qlinea.com.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

Q-linea announces determined exercise price for warrants series TO 1 and update regarding subscription intentions